Emmaus Life Sciences Reports Annual Financial Results

Emmaus Life Sciences Reports Annual Financial Results Emmaus Life Sciences Reports Annual Financial Results Share TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial- stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2025. Highlights "We experienced a 25% decline in net revenues in 2025 as compared to 2024 due to ongoing competi ...